Literature DB >> 16291284

Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission.

Myoung Kuk Jang1, Dae Ro Choi, Ja Young Lee, Han Kook Moon, Jun Ho Lee, Seong Man Kim, Kyung Ho Kim, Joon Yong Park, Jin Heon Lee, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park, Jae Young Yoo.   

Abstract

This study was to evaluate responsiveness to IFN-alpha and investigate the benefits of sustained response (SR) in patients who were presumed as being vertically transmitted in Korea. A total of 46 patients of presumed vertical transmission with biopsy-proven HBeAg-positive chronic HBV infection were treated with IFN-alpha and followed. We tried to find the factors associated with SR and compared the cumulative rate of HCC and survival between SR group and non-sustained/non-responder (NSR) group. HBeAg loss was acquired in 35% (16/46) within a year but SR was observed in 22% (10/46). Age <35 years and ALT levels >7xULN were significant favorable factors for SR (OR 0.56, 0.49, 95%CI 0.38-0.82, 0.29-0.81, respectively) (both P<0.05). There were no significant differences of cumulative HCC-free survival (100 vs. 68% at 12 years, P=0.36) and survival (100 vs. 73% at 12 years, P=0.3) between SR group and NSR group. In conclusion, age below 35 years old and serum ALT levels above 7xULN may predict IFN-alpha therapy-induced SR among them, although we cannot affirm the effects on HCC prevention or survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291284     DOI: 10.1016/j.jinf.2005.01.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  1 in total

1.  Phylogenetic analyses of HBV pre-s/s genes in mother-child pairs with long-term infection by presumed vertical transmission.

Authors:  Hyoung Su Kim; Bo Youn Choi; Hyeok Soo Choi; Woon Geon Shin; Kyung Ho Kim; Jin Heon Lee; Hak Yang Kim; Myoung Kuk Jang; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.